Original Research
Published on 01 Sep 2023
Efficacy and safety of anlotinib plus XELOX regimen as first-line therapy for mCRC: a single-arm, multicenter, phase II study (ALTER-C-001)
in Gastrointestinal Cancers: Colorectal Cancer
- 2,225 views
- 2 citations